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A b s t r a c t
Background: Acute hyperglycaemia is an adverse prognostic factor in patients with acute coronary syndrome (ACS). It is
unclear whether these negative effects apply equally to patients with diabetes mellitus (DM) and non-DM patients.
Aim: To evaluate the short-term (in-hospital) and long-term (four-year) prognostic value of acute hyperglycaemia in ACS
patients with or without DM.
Methods: The study involved 116 ACS patients admitted between 2004 and 2006 to our department, who were selected for
invasive treatment and who had both admission and first fasting glucose levels measured. Patients were classified as DM (n = 23),
on the basis of a known history of diabetes or newly detected diabetes, or non-DM (n = 93). Acute hyperglycaemia was defined
as an admission glycaemia ≥ 10.0 mmol/L (180 mg/dL) for non-DM patients, or ≥ 7.8 mmol/L (140 mg/dL) for DM patients, or
a first fasting glucose level ≥ 5.6 mmol/L (100 mg/dL) for both DM and non-DM patients. The primary end-point was defined as
mortality during follow-up. The secondary end-points were death, cardiac arrest or repeated ACS occurrence, stroke or transient
ischaemic attack, and the need for repeat percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
procedure during the in-hospital and four-year post-hospital periods. During follow-up, patients were assessed for a composite
end-point defined as all-cause death, repeated ACS occurrence, repeat PCI or CABG procedure, and stroke.
Results: Acute hyperglycaemia was present in 28 non-DM and 14 DM patients. The mean follow-up time was 4 ± 0.6 years.
For DM patients, there was no significant difference in four-year mortality between hyperglycaemic and normoglycaemic
patients (14.3% vs 11.1%, respectively; NS). The occurrence of secondary end-points and composite end-point frequency
was also similar for these subgroups, both for in-hospital and four-year observations. For non-DM patients, the four-year
mortality was similar for hyperglycaemic and normoglycaemic subjects (17.9% vs 10.8%, respectively; NS), whereas cardiac
arrest during the in-hospital period was more common for hyperglycaemic than normoglycaemic patients (3.6% vs 0.0%, respecti-
vely; n = 1 vs 0; p = 0.01). The composite end-point for the in-hospital period was reached by 17.6% of hyperglycaemic and 13.8%
of normoglycaemic non-DM patients (NS). The composite end-point during the four-year observation period was more frequently
reached in hyperglycaemic than in normoglycaemic non-DM patients (78.6% vs 56.9%, respectively; p = 0.04).
Conclusions: Acute hyperglycaemia in non-DM patients hospitalised due to ACS was found to be an unfavourable long-term
(four-year) risk factor, and may also be an unfavourable in-hospital risk factor. In contrast, acute hyperglycaemia did not affect
cardiovascular outcomes in DM patients.
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INTRODUCTION
Abnormal glucose metabolism including impaired fasting gly-
caemia, impaired glucose tolerance and diabetes mellitus (DM)
are important and independent ischaemic heart disease risk
factors, and have a negative impact on outcomes of patients
with an acute coronary syndrome (ACS) [1].
Acute hyperglycaemia is also known as hyperglycaemia
of the acute phase, or stress hyperglycaemia, and is defined
as an increase in blood glucose level due to acute, severe
injury (e.g. ACS). Recent studies have reported that elevated
glucose level in ACS patients was associated with an incre-
ased risk of in-hospital and long-term complications, both in
DM and non-DM patients [2, 3]. Increased glucose levels at
admission are associated with a higher Killip class, a larger
infarct and worse left ventricular (LV) function [4]. In-hospital
infections, pulmonary oedema, ventricular tachycardia, atrial
fibrillation, ventricular fibrillation, pre-hospital and in-hospi-
tal cardiac arrest or cerebrovascular incidents have also been
reported as being more frequent in patients with elevated glu-
cose levels at admission [4].
There are limited data regarding the effects of acute hy-
perglycaemia on long-term outcomes in ACS patients with or
without DM. Only a few studies with follow-up longer than
one year investigated the prognostic value of acute hypergly-
caemia in DM patients and non-DM subjects. Moreover, these
studies used different definitions of hyperglycaemia, which
were based on a single glucose measurement, either at ad-
mission or at first fasting [3, 5].
The present study investigated the effects of hyperglyca-
emia in ACS patients with and without DM on the short-term
(in-hospital) and long-term (four-year) outcomes.
METHODS
Study population
The study involved patients who were selected for an urgent
invasive diagnosis and treatment of ischaemic heart disease
and were hospitalised due to ACS between 2004 and 2006
in our department. The ACS was defined as unstable angina,
myocardial infarction with ST segment elevation (STEMI), or
MI without ST segment elevation (NSTEMI). The study recru-
ited 116 patients who agreed to participate and whose glyca-
emic status during hospitalisation was known. Both admis-
sion glycaemia and first fasting glycaemia were measured. In
patients without previously known diabetes, an oral glucose
test (OGTT) was performed on or after the fourth day of ho-
spitalisation to identify any glucose metabolism abnormali-
ties. In case of multiple hospitalisations due to ACS during
the study period, only data from the first hospitalisation were
analysed. We evaluated demographic data, angiographic pa-
rameters, i.e. percutaneous coronary intervention (PCI) pro-
cedure, effectiveness of PCI on the basis of the TIMI scale
where TIMI 3 flow was considered as effective, three-vessel
coronary artery disease (CAD) presence, electrocardiographic
changes and selected biochemical measurements, i.e. maxi-
mum levels of troponin I and creatine kinase, lipidogram,
glucose levels on admission and at first fasting, and OGTT
results. Patients were assessed for the presence of the follo-
wing risk factors in their history and up to the final follow-up
visit: smoking status, obesity (body mass index > 30 kg/m2),
hypertension (systolic pressure ≥ 140 mm Hg and/or dia-
stolic pressure ≥ 90 mm Hg), and hypercholesterolaemia
(total cholesterol level ≥ 4.5 mg/dL or LDL cholesterol level
> 2.5 mg/dL). All patients underwent echocardiography (HP
Sonos 5500) to assess LV ejection fraction (LVEF) (Teihcholz’s
or Simpson’s method or eyeball evaluation of two-dimensio-
nal projections). Four-year follow-up data was obtained du-
ring visits (99 patients) or via telephone or written question-
naires (17 patients).
Glucose concentration was measured from venous blo-
od samples on admission and the next day following an over-
night fast of more than eight hours (i.e. first fasting). For analy-
sis, patients were placed into DM or non-DM groups. The
DM group consisted of patients known to have DM, and pa-
tients who were not previously known to have DM but were
newly diagnosed with DM during hospitalisation on the basis
of OGTT performed at the end of hospitalisation (i.e. after
the acute phase of ACS, on or after the fourth day of hospi-
talisation). A diagnosis of DM was based on a glucose level
≥ 11.1 mmol/L 120 min after a 75-g oral glucose load. The
non-DM group consisted of the remaining patients.
All patients were categorised as normoglycaemic or hy-
perglycaemic based on both admission and first fasting glucose
levels. Adhering to the recommendations of the Polish Diabe-
tic Association for hypoglycaemic treatment in states of ”relati-
ve hypoglycaemia”, patients were classified as hyperglycaemic
if the admission glucose level was ≥ 7.8 mmol/L (140 mg/dL)
for DM patients or ≥ 10.0 mmol/L (180 mg/dL) for non-DM
patients [6], or if the first fasting glucose level was ≥ 5.6 mmol/L
(100 mg/dL) for either DM or non-DM patients.
End-points
The primary end-point was defined as mortality during the
four-year follow-up period. Secondary end-points were defi-
ned as death, sudden cardiac arrest, repeated MI, stroke or
transient ischaemic attack (TIA), and the need for coronary
artery bypass grafting (CABG) or PCI (both elective and unsche-
duled) during the in-hospital and four-year follow-up periods.
The composite end-point for in-hospital stay was defi-
ned as the occurrence of at least one of the following: death,
sudden cardiac arrest, repeated MI, stroke or TIA, the need
for urgent CABG, and repeated PCI. The composite end-po-
int for the four-year follow-up was defined as the occurrence
after hospitalisation at least one of the following: death from
any cause, repeated MI, PCI, CABG, stroke or TIA.
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The study protocol was approved by the Bioethics Com-
mittee of Jagiellonian University (KBET/47/B/2010).
Statistical analysis
Continuous variables with normal distribution are presented
as mean ± SD, and differences were analysed using Student’s
t-test. The non-parametric Mann-Whitney U test was used
to compare non-normally distributed variables. The c2 test
was used to determine the significance of associations be-
tween categorical variables. If expected frequencies were less
than five, a c2 tests with Yates’ correction was used, and Fi-
sher’s exact test was used when the total number of observa-
tions was small. A p value < 0.05 was considered significant.
Statistical analysis was performed using Statistica PL software
version 8.0.
RESULTS
Of the 116 patients, 23 were classified as DM (including five
patients with newly diagnosed DM) and 93 were classified
as non-DM. The mean follow-up period was 4 ± 0.6 years
(> four years in 62% of patients). In both the DM and the
non-DM group, normoglycaemic and hyperglycaemic pa-
tients did not differ with respect to age, sex, incidence of
hypertension, hypercholesterolaemia, smoking, obesity, type
of ACS or the distribution of arteries responsible for ACS
(Tables 1, 2). In DM patients, hyperglycaemia and nor-
moglycaemia groups did not differ in the frequency of hi-
story of MI. In-hospital mortality tended to be higher in non-
-DM than DM patients (13.0% vs 3.2%; p = 0.06) whereas
mortality after hospitalisation was similar (15.0% vs 15.1%;
p = 0.95, respectively).
Subjects with diabetes mellitus
Of the 23 DM patients, 14 (61%) were classified as hypergly-
caemic, and nine (39%) were classified as normoglycaemic
(Table 1). During the in-hospital period, hyperglycaemic DM
patients were more commonly found to have three-vessel
CAD than normoglycaemic DM patients (35.7% vs 0.0%;
p = 0.04). Although hyperglycaemic DM patients tended to
undergo PCI less frequently than normoglycaemic DM
patients, the difference was not significant (71.4% vs 100.0%;
p = 0.08). The incidence of TIMI 3 flow after the procedure
was similar in both groups (Table 2). In hyperglycaemic DM
patients with STEMI, the biomarkers for myocardial necrosis
Table 1. Comparison of baseline demographic and clinical characteristics as well as in-hospital parameters between hyperglycaemic
and normoglycaemic patients
Patients with DM (n = 23) Patients without DM (n = 93)
Hyperglycaemia Normoglycaemia P Hyperglycaemia Normoglycaemia P
N = 14 (61%) N = 9 (39%) N = 28 (30%) N = 65 (70%)
Age [years] [median; 61.6 ± 9.5 60.4 ± 9.7 0.33 61.4 ± 12.1 61.3 ± 12.1 0.98
interquartile range] [67; 57–73] [57; 53–70] [60; 53–70] [63; 51–70]
Male gender 9 (64.3%) 4 (44.4%) 0.61 25 (89.3%) 53 (81.53%) 0.29
Hypertension 13 (92.8%) 8 (88.9%) 0.74 18 (64.3%) 50 (76.9%) 0.21
Hypercholesterolaemia 8 (57.1%) 4 (44.4%) 0.87 16 (57.1%) 39 (60.0%) 0.80
Smokers 4 (28.6%) 2 (22.2%) 0.88 13 (46.4%) 26 (40.0%0 0.56
Obesity 4 (28.6%) 3 (33.3%) 0.82 6 (21.4%) 4 (6.2%) 0.08
History of previous MI 4 (28.6%) 3 (33.3%) 0.82 4 (14.3%) 21 (32.3%) 0.07
Glucose level on admission 12.34 ± 4.53 6.23 ± 1.05 0.01 8.81 ± 3.23 6.69 ± 2.95 0.01
(mean mmol/L) [median; [10.5; 9–15.7] [6.7; 5.4–6.8] [8.0; 6.9–9.7] [6.35; 5.7–72]
interquartile range]
First fasting glucose level 9.54 ± 3.74 5.53 ± 0.31 0.02 6.23 ± 0.93 5.22 ± 0.89 0.01
(mean mmol/L) [median; [7.3; 6.5–12.1] [5.45; 5.4–5.5] [6.15; 5.6–6.7] [5.1; 4.66–5.45]
interquartile range]
STEMI 10 (71.4%) 6 (66.7%) 0.80 21 (75.0%) 44 (67.7%) 0.48
NSTEMI 3 (21.4%) 3 (33.3%) 0.88 4 (14.3%) 19 (29.2%) 0.12
Unstable angina 1 (7.1%) 0 (0%) 0.82 3 (10.7%) 2 (3.1%) 0.66
Anterior wall MI 4 (28.6%) 1 (11.1%) 0.63 7 (25.0%) 10 (15.4%) 0.27
Newly detected DM 2 (14.3%) 3 (33.3%) 0.57 – – –
DM — diabetes mellitus; MI — myocardial infarction; NSTEMI — non-ST segment elevation myocardial infarction; STEMI — ST segment elevation
myocardial infarction
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were higher compared to normoglycaemic DM patients
with STEMI (20.76 ± 19.25 vs 1.74 ± 0.89 ng/mL troponin I;
p = 0.02) (Table 3).
During the in-hospital observation period the need for
urgent CABG, repeated ACS occurrence, frequency of stroke
or TIA, sudden cardiac arrest, all-cause death, repeated PCI
procedure and LVEF value was similar in hyperglycaemic and
normoglycaemic DM patients. The composite end-point was
reached in 28.6% of hyperglycaemic and 11.2% of normo-
glycaemic DM patients (NS). Also during the four-year fol-
low-up period (after index hospitalisation) the outcome of
both subgroups was similar (Table 3).
Subjects without diabetes mellitus
Of the 93 non-DM patients, 28 (30%) were classified as hy-
perglycaemic and 65 (70%) as normoglycaemic. A history
of MI was more prevalent in the normoglycaemic group (Ta-
ble 1). Hyperglycaemic and normoglycaemic non-DM pa-
tients had similar incidence of three-vessel CAD (21.4% vs
18.4%; NS), PCI procedure (75.0% vs 80.0%; NS) and TIMI
3 flow after PCI (100% vs 98.1%; NS) (Table 2).
During the in-hospital observation period, hyperglyca-
emic and normoglycaemic non-DM patients had similar inci-
dence of urgent CABG, repeated ACS stroke or TIA, repeated
PCI procedure and LVEF value. Sudden cardiac arrest occur-
red more frequently in hyperglycaemic subjects (3.6% vs 0.0%;
n = 1 vs 0; p = 0.01). The composite end-point was reached
in 17.6% of hyperglycaemic and 13.8% of normoglycaemic
non-DM subjects (NS) (Table 3).
During the four-year follow-up period, hyperglycaemic
and normoglycaemic non-DM patients had similar incidence
of all-cause death, repeated MI, PCI, CABG, stroke and TIA.
However, hyperglycaemic subjects were more likely to reach
the composite end-point than normoglycaemic subjects
(78.6% vs 56.9%; p = 0.04).
During the four-year follow-up period, newly diagnosed
DM was reported in 17% of hyperglycaemic patients and in
12% of normoglycaemic patients during the acute phase of
ACS (NS) (Table 3).
DISCUSSION
This four-year observational study found that hyperglycaemia
in the acute phase of ACS was associated with a higher inci-
dence of unfavourable cardiovascular (CV) events in non-DM
patients, but did not influence CV outcomes in DM patients.
Moreover, in hyperglycaemic non-DM patients, in-hospital
sudden cardiac arrest was more frequent compared to nor-
moglycaemic non-DM patients.
The mechanisms underlying the development of hyper-
glycaemia in ACS patients remain inadequately understood.
Acute hyperglycaemia is usually regarded as a reaction to
stress, and in ACS, stress reaction is directed toward short-
-term optimisation of CV function. Other possible causes of
acute hyperglycaemia are undiagnosed DM and glucose me-
tabolism disorders, and although such chronic conditions can
be managed, it may not be possible to normalise them in
cases of severe disease and ‘metabolic storm’. It may be that
glycaemia on admission is not only a marker of acute stress,
but also reflects the current metabolic status. Furthermore,
the unfavourable effects of hyperglycaemia on the prognosis
for ACS patients may result from intensification of inflamma-
tory conditions [7].
Table 2. Comparison of angiographic characteristics between hyperglycaemic and normoglycaemic patients
Patients with DM (n = 23) Patients without DM (n = 93)
Hyperglycaemia Normoglycaemia P Hyperglycaemia Normoglycaemia P
N = 14 (61%) N = 9 (39%) N = 28 (30%) N = 65 (70%)
Baseline TIMI 0–1 11 (78.6%) 5 (55.6%) 0.24 17 (60.7%) 31 (47.7%) 0.25
TIMI 3 after PCI 10 (100%) 9 (100%) – 21 (100%) 51 (98.1%) 0.52
IRA:
LMCA 0 (0%) 0 (0%) – 1 (3.6%) 6 (9.2%) 0.60
LAD 6 (42.9%) 4 (44.4%) 0.72 11 (39.3%) 24 (36.9%) 0.82
Cx 1 (7.1%) 0 (0%) 0.82 3 (10.7%) 10 (15.4%) 0.78
RCA 7 (50.0%) 4 (44.4%) 0.86 6 (21.4%) 13 (20.0%) 0.93
Single-VD 4 (28.6%) 4 (44.4%) 0.74 9 (32.1%) 31 (47.7%) 0.16
Two-VD 5 (35.7%) 4 (44.4%) 0.98 7 (25.0%) 17 (26.1%) 0.90
Three-VD 5 (35.7%) 0 (0%) 0.04 6 (21.4%) 12 (18.5%) 0.80
PCI procedure 10 (71.4%) 9 (100%) 0.08 21 (75.0%) 52 (80.0%) 0.59
Stent implantation 7 (50.0%) 6 (66.7%) 0.43 17 (60.7%) 41 (63.1%) 0.83
DM — diabetes mellitus; Cx - circumflex artery; LAD — left anterior descending artery; LMCA — left main coronary artery; RCA — right coronary artery;
VD — vessel disease; PCI — percutaneous coronary intervention; TIMI — Thrombolysis In Myocardial Infarction; IRA — infarction related artery
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Table 3. Comparison of in-hospital parameters and long-term follow-up outcome between hyperglycaemic and normoglycaemic
patients
Patients with DM (n = 23) Patients without DM (n = 93)
Hyperglycaemia Normoglycaemia P Hyperglycaemia Normoglycaemia P
N = 14 (61%) N = 9 (39%) N = 28 (30%) N = 65 (70%)
Max. troponin I concentration 19.53 ± 19.1 1.35 ± 1.07 0.02 14.8 ± 17.12 12.18 ± 16.18 0.56
all ACS types [ng/mL] [9.55; 4.5–33] [1.14; 0.1–2.25] [4.2; 1.99–30] [3.45; 0.28–15.9]
[median; interquartile range]
Max. CK concentration 1610 ± 1339 930 ± 1577 0.29 2766 ± 2981 1458 ± 2509 0.04
all ACS types [U/L] [1234; 596–2437] [324; 110.5–867.5] [1499; 665–4713] [535; 81–1403]
[median; interquartile range]
Max. troponin I concentration 20.76 ± 19.25 1.74 ± 0.89 0.02 17.8 ± 16.3 16.5 ± 18.4 0.70
STEMI patients [ng/mL] [10.17; 6.31–33] [1.52; 1.07–24.2] [8.24; 3.02–33.5] [8.09; 1.85–26.67]
[median; interquartile range]
Max. CK concentration 1706 ± 1344 1652 ± 2093 0.96 3066 ± 3064 1953 ± 2634 0.09
STEMI patients [U/L] [1403; 597–2437] [86.75; 495–2820] [1469; 695–4871] [1931; 494–2260]
[median; interquartile range]
SCA during hospitalisation 0 (0%) 0 (0%) – 1 (3.6%) 0 (0%) 0.01
HF during hospitalisation 2 (14.3%) 0 (0%) 0.67 2 (7.1%) 1 (1.5%) 0.44
Stroke during hospitalisation 0 (0%) 0 (0%) – 0 (0%) 0 (0%)
Need for urgent CABG 2 (14.3%) 0 (0%) 0.36 3 (10.7%) 8 (12.3%) 0.89
Repeated PCI procedure 0 (0%) 0 (0%) – 0 (0%) 0 (0%) –
during hospitalisation
Repeated ACS occurrence 0 (0%) 0 (0%) – 0 (0%) 0 (0%) –
during hospitalisation
Ejection fraction [%] 48 ± 11.53 49 ± 10.8 0.86 49.75 ± 9.96 52.74 ± 9.86
[median; interquartile range] [50; 37–65] [48; 45–50] [50; 45–57] [54.5; 50–60]
Time of hospitalisation (days) 9.21 ± 6.13 6.12 ± 2.8 0.19 7.36 ± 3.89 6.15 ± 3.42 0.16
[median; interquartile range] [7; 5–10] [5.5; 4.5–7] [7; 5–8] [6; 4–7]
In-hospital mortality 2 (14.3%) 1 (11.1%) 0.68 2 (7.1%) 1 (1.5%) 0.44
Composite end-point during 4 (28.6%) 1 (11.1%) 0.33 5 (17.9%) 9 (13.8%) 0.62
in-hospital observation period
Mortality during follow-up period 2 (14.3%) 1 (11.1%) 0.68 5 (17.9%) 7 (10.8%) 0.35
Repeated ACS occurrence 4 (28.6%) 1 (11.1%) 0.33 5 (17.9%) 9 (13.8%) 0.62
during follow-up period
Repeated PCI procedure 3 (21.4%) 4 (44.4%) 0.48 7 (25%) 10 (15.4%) 0.27
during follow-up period
CABG during follow-up period 1 (7.1%) 0 (0%) 0.82 5 (17.9%) 9 (13.8%) 0.62
Stroke or TIA during 1 (7.1%) 0 (0%) 0.82 1 (3.6%) 4 (6.1%) 0.96
follow-up period
Composite end-point 9 (64.3%) 6 (66.7%) 0.90 22 (78.6%) 37 (56.9%) 0.04
during follow-up period
Newly diagnosed diabetes – – – 5 (17.9%) 8 (12.3%) 0.48
after hospital discharge
ACS — acute coronary syndrome; DM — diabetes mellitus; CABG — coronary artery bypass grafting; CK — creatine kinase; HF — heart failure;
PCI — percutaneous coronary intervention; SCA — sudden cardiac arrest; TIA — transient ischaemic attack
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Acute hyperglycaemia is associated with a higher risk of
in-hospital complications in ACS patients, independent of
a prior diagnosis of DM [2, 3, 8]. Some reports have sugge-
sted that this association results in a similar risk of complica-
tions in both DM and non-DM patients [3], although other
authors reported the higher risk in non-DM patients [2, 9].
Studies examining the effects of acute hyperglycaemia on the
long-term prognosis of ACS patients are limited, and have
maximal follow-up of only three years [9, 10].
Similar findings to our study were presented by Monte-
iro et al. [9], who reported that increased glucose levels on
admission were associated with higher mortality rates during
both in-hospital and three-year follow-up in non-DM patients,
but not in DM patients. In a one-year observational study of
1,310 STEMI patients (352 DM [26.9%] vs 958 non-DM
[73.1%] patients), Gąsior et al. [10] reported that increased
glucose levels measured in the acute phase of MI affected the
prognosis in non-DM patients, but was not an independent
risk factor of death in DM patients treated with PCI. Ishihara
et al. [11] found that hyperglycaemia on admission was a short-
-term risk factor in STEMI patients, but did not correlate with
mortality during the period of 30 days to three years after MI.
They also found that there was no association between DM
and mortality during short-term follow-up, but that DM influ-
enced the long-term prognosis. The apparent discrepancies
between the findings of the various studies may reflect diffe-
rent glucose levels being used to define hyperglycaemia.
A precise and widely acceptable biochemical definition
of acute hyperglycaemia has yet to be established. In stu-
dies evaluating the impact of acute hyperglycaemia on out-
comes during ACS, the threshold level of hyperglycaemia
has varied between 6.7 and 11.1 mmol/L (120–200 mg/dL)
for admission glycaemia, and between 6.1 and 8.0 mmol/L
(110–144 mg/dL) for the first fasting glucose level [11–14].
In our study, hyperglycaemia was defined as an admission
glycaemia above 140 mg/dL (7.8 mmol/L) in DM patients
and above 180 mg/dL (10.0 mmol/L) in non-DM patients,
in accordance with the recommendations of the Polish Dia-
betes Association on hypoglycaemic treatment in states of
“relative hyperglycaemia” [6].
We believe that using both admission and first fasting
glycaemia measurements is crucial when classifying ACS pa-
tients as normoglycaemic or hyperglycaemic because it pro-
vides a more reliable and precise evaluation of the real state
of carbohydrate metabolism compared to using either me-
asurement alone. Indeed, others have reported that use of
a single glucose measurement is not an optimal diagnostic
tool for estimating carbohydrate metabolism [15, 16]. Altho-
ugh there are some doubts about the reliability of OGTT in
diagnosing DM in ACS patients, reports from the GAMI Study
on OGTT in MI [17] and the results of Swedish studies [18]
suggest that OGTT is a reliable method of diagnosing glucose
metabolism disturbances in patients with ACS, but only when
it is performed after the early phase of MI (fourth day or later).
We found that the glycaemic status did not affect in-ho-
spital mortality or the long-term incidence of unfavourable
CV events in DM patients. We found that there were no si-
gnificant differences between the normo- and hyperglycaemic
subgroups in the frequency of CV risk factors. These results
are consistent with findings from the study by Kosiborod et
al. [19], in which hyperglycaemia was found not to be asso-
ciated with an increase in in-hospital or one-year mortality in
ACS patients with DM, with the exception of patients with
a glucose level > 240 mg/dL.
We found that three-vessel CAD was more common in
DM than non-DM patients, and as a consequence, urgent
CABG procedures were more often performed in hypergly-
caemic DM patients. It is possible that hyperglycaemia in dia-
betics, as a marker of carbohydrate metabolism disturbance,
might be a chronic state responsible for diffuse atherosclero-
tic changes developing in a younger age, and may lead to
more frequent occurrence of three-vessel CAD.
In the current study, normoglycaemic and hyperglyca-
emic non-DM patients had comparable in-hospital mortali-
ty. However, normoglycaemic and hyperglycaemic non-DM
patients differed in terms of the frequency of obesity and a hi-
story of prior MI. We found that hyperglycaemia in ACS pa-
tients with DM was associated with a larger area of myocar-
dial necrosis (a difference in the level of myocardial necrosis
markers was observed in the STEMI subgroup). These results
are in accordance with those of the Global Registry of Acute
Coronary Events (GRACE) which reported that higher levels
of admission glycaemia were associated with increased MI
size [5].
Limitations of the study
This study was a retrospective pilot analysis of a relatively small
number of patients treated in a single centre.
CONCLUSIONS
1. Hyperglycaemia is an unfavourable long-term progno-
stic factor, and may also be an unfavourable factor du-
ring the in-hospital stay, in patients hospitalised due to
ACS who are not diabetic.
2. Hyperglycaemia does not appear to affect either the in-
hospital or four-year clinical outcomes in patients hospi-
talised due to ACS who are diabetic.
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Wpływ ostrej hiperglikemii na rokowanie wewnątrz−
szpitalne i długoterminowe u pacjentów z ostrymi
zespołami wieńcowymi — badanie pilotażowe
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S t r e s z c z e n i e
Wstęp: Ostra hiperglikemia jest niekorzystnym czynnikiem rokowniczym u pacjentów z ostrymi zespołami wieńcowymi
(OZW). Istnieją rozbieżne dane dotyczące wpływu ostrej hiperglikemii na rokowanie w zależności od obecności lub braku
rozpoznania cukrzycy.
Cel: Celem pracy była ocena wpływu ostrej hiperglikemii u chorych z OZW na rokowanie wewnątrzszpitalne i odległe
(obserwacja 4-letnia) u pacjentów bez cukrzycy i u chorych z rozpoznaną cukrzycą.
Metody: U 116 pacjentów hospitalizowanych w latach 2004–2006 w I Klinice Kardiologii i Nadciśnienia Tętniczego Szpitala
Uniwersyteckiego w Krakowie z powodu OZW, zakwalifikowanych do pilnej diagnostyki inwazyjnej choroby niedokrwien-
nej serca, oznaczano stężenie glukozy w krwi żylnej w chwili przyjęcia do szpitala oraz następnego dnia na czczo. Chorych
podzielono na dwie grupy: z rozpoznaną cukrzycą (przed epizodem OZW lub w trakcie hospitalizacji) oraz bez cukrzycy,
wyodrębniając w obu grupach osoby z hiperglikemią i normoglikemią. Ostrą hiperglikemię definiowano jako stężenie glukozy
przy przyjęciu ≥ 10,0 mmol/l (180 mg/dl) w grupie osób bez cukrzycy, w grupie pacjentów z cukrzycą ≥ 7,8 mmol/l (140 mg/dl)
lub pierwszą glikemię na czczo ≥ 5,6 mmol/l (100 mg/dl) (w obu grupach). Ostrą hiperglikemię stwierdzono u 14 chorych na
cukrzycę oraz u 28 pacjentów bez cukrzycy. Średni czas obserwacji wynosił 4 ± 0,6 roku. Za pierwotny punkt końcowy
przyjęto śmiertelność 4-letnią. Wtórne punkty końcowe stanowiły: zgon, nagłe zatrzymanie krążenia, ponowny zawał serca,
udar mózgu lub przejściowy epizod niedokrwienny mózgu (TIA), konieczność pilnego zabiegu pomostowania aortalno-
wieńcowego (CABG) lub powtórnej angioplastyki (PCI) w obserwacji wewnątrzszpitalnej i 4-letniej. Złożony punkt końcowy
w obserwacji wewnątrzszpitalnej i 4-letniej zdefiniowano jako wystąpienie co najmniej 1 zdarzenia spośród: zgonu z jakiego-
kolwiek powodu, ponownego zawału serca, udaru mózgu, konieczności powtórnej PCI lub CABG.
Wyniki: U pacjentów z cukrzycą śmiertelność 4-letnia nie różniła się istotnie między grupą chorych z hiperglikemią i normoglike-
mią (14,3% v. 11,1%; p = NS). Wtórne punkty końcowe i złożony punkt końcowy w tej grupie pacjentów wystąpił z podobną
częstością w podgrupie z hiperglikemią i normoglikemią, zarówno w okresie wewnątrzszpitalnym, jak i w trakcie 4-letniej obser-
wacji. Wśród pacjentów bez cukrzycy śmiertelność 4-letnia również nie różniła się istotnie w podgrupie z hiperglikemią i normogli-
kemią (17,9% v. 10,8%; p = NS). U chorych z hiperglikemią istotnie częściej dochodziło do nagłego zatrzymania krążenia w trak-
cie pobytu w szpitalu (3,6% v. 0,0%; n: 1 v. 0; p = 0,01). Złożony punkt końcowy w obserwacji wewnątrzszpitalnej wystąpił
u 17,6% osób z hiperglikemią i u 13,8% osób z normoglikemią (p = NS). Złożony punkt końcowy w obserwacji 4-letniej stwier-
dzono istotnie częściej w podgrupie z hiperglikemią w porównaniu z pacjentami z normoglikemią (78,6% v. 56,9%; p = 0,04).
Wnioski: U osób bez cukrzycy hospitalizowanych z powodu OZW hiperglikemia stanowi niekorzystny czynnik rokowniczy
w obserwacji długoterminowej, może też być niekorzystnym czynnikiem rokowniczym w obserwacji wewnątrzszpitalnej.
Ostra hiperglikemia u chorych na cukrzycę hospitalizowanych z powodu OZW nie wpływa na częstość zdarzeń sercowo-
-naczyniowych w obserwacji wewnątrzszpitalnej i 4-letniej.
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